- Home
- DATS vs ERNA Comparison
DATS vs ERNA Comparison
Compare DATS & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- ERNA
- Stock Information
- Founded
- DATS 2014
- ERNA 2018
- Country
- DATS United States
- ERNA United States
- Employees
- DATS N/A
- ERNA N/A
- Industry
- DATS Computer Software: Prepackaged Software
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- ERNA Health Care
- Exchange
- DATS Nasdaq
- ERNA Nasdaq
- Market Cap
- DATS 13.4M
- ERNA 13.5M
- IPO Year
- DATS 2021
- ERNA N/A
- Fundamental
- Price
- DATS $2.66
- ERNA $1.62
- Analyst Decision
- DATS
- ERNA
- Analyst Count
- DATS 0
- ERNA 0
- Target Price
- DATS N/A
- ERNA N/A
- AVG Volume (30 Days)
- DATS 88.3K
- ERNA 88.1K
- Earning Date
- DATS 08-22-2025
- ERNA 08-22-2025
- Dividend Yield
- DATS N/A
- ERNA N/A
- EPS Growth
- DATS N/A
- ERNA N/A
- EPS
- DATS N/A
- ERNA N/A
- Revenue
- DATS $388.00
- ERNA $535,000.00
- Revenue This Year
- DATS N/A
- ERNA N/A
- Revenue Next Year
- DATS N/A
- ERNA N/A
- P/E Ratio
- DATS N/A
- ERNA N/A
- Revenue Growth
- DATS N/A
- ERNA 365.22
- 52 Week Low
- DATS $1.11
- ERNA $1.50
- 52 Week High
- DATS $9.34
- ERNA $29.25
- Technical
- Relative Strength Index (RSI)
- DATS 55.66
- ERNA 37.12
- Support Level
- DATS $2.25
- ERNA $1.60
- Resistance Level
- DATS $2.46
- ERNA $1.74
- Average True Range (ATR)
- DATS 0.14
- ERNA 0.19
- MACD
- DATS 0.01
- ERNA -0.00
- Stochastic Oscillator
- DATS 87.00
- ERNA 11.21
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.